Welcome, everyone, to 2026 Jefferies Global Healthcare Conference in London. My name is Roger Song, Senior Analyst, covers biotech in the U.S. It is my great pleasure to have the fireside chat with Wave Life Sciences, and we have a CEO, Paul Bolno. Welcome.
Roger, thanks for having us.
Awesome. All right, I think we have a lot to cover. Why don't we just go right into it? INHBE still be the probably top of the people's mind. We just came back from ObesityWeek. A lot of the non-incretin, the amylin activity there. Most of them are preclinical. You are leading the pack there. Maybe just start with that. I don't know if you were there, but at least your team probably have some key take for you.
That's the same in the present, so yeah.
Yeah. That is right. What is your key take from this ObesityWeek and then related to your program?
Yeah, no, it is a very timely conversation because this time of year, we get to reflect both on last year and then this year. If we think about the evolution, I think, at ObesityWeek, if last year was this focus on, there was this race, what we call, it was like almost like a nuclear arms race to weight reduction almost at any expense. With the opening that people were recognizing that there is different quality, like how do we think about fat, how do we think about muscle, but there were a number of programs.
I would say this year was palpably a shift towards a focus on two areas of importance, and I think they line up, to your point, exquisitely well with the mechanism of INHBE and the path we are taking, which is, one, a real reflection on quality of weight loss and body composition. So, discussion on, what do we really mean when we say weight loss? Are we talking about scale weight loss, or are we really talking about body composition improvement, meaning fat loss, visceral fat, subcutaneous fat, but lean mass preservation? I think that was a key driver.
I think there is a realization from the KOLs in the space that this idea of losing lean mass at the expense of a number and percent body weight reduction is not the answer to solving the crisis, and realizing that actually keeping and retaining lean muscle mass actually potentiates further fat reduction and fat maintenance because it is an endocrine organ involved in insulin sensitivity. So, that concept of quality of weight loss, body composition was one feature. I think the other conversation, which again, is also very timely for INHBE, is a real conversation that now with incretins on the market so long and with the idea that these are, it is kind of now ubiquitous, people talk about it all the time, is the conversation really evolving to, "My patient achieved whatever this goal is," right?
And then, we see this even in individual conversations with people who are self-prescribed. They are like, "I am at my goal." There is this desire of getting to whatever that is for various different individuals. What is next? I think that conversation that physicians and patients are really starting to have, and frankly, payers for that matter, are saying, "We are getting this health benefit, but the health benefit is only sustained if a patient stays at a particular moment in time."
I think what we are seeing now is this notion of, what do we do? Because 70% of patients are not staying on their incretin. We know that people are coming off of those medicines, and we know there is a lot of hesitancy of what that transition looks like. This concept, and there are different ways of calling it. We like to refer to that as maintenance.
What does maintenance of this weight loss look like? If we think about the two most important pillars of what INHBE can do, one is body composition improvements and what you see mechanistically when you have a medicine that drives loss of fat and preservation of muscle. Secondly, so long as that effect is sustained, an opportunity, I think these are the two really most interesting areas for INHBE therapies. We can talk about, and I think it is important to spend time, and we can do that afterwards, on the genetics of the target, the data on the target, and why we think this target has implications for both body composition improvements and also what maintenance starts to look like long term to realize real health outcome benefits for patients and payers.
Excellent. As always, you teed up pretty well. I think we can pass out a couple components you just mentioned, the comments. First of all, the high-quality weight loss, right? You are running a phase II trial, and then try to enroll the patient with a little bit higher BMI, and then which will likely going to see more benefit from the INHBE mechanism because it is more fat-driven and not fat loss-driven. What is your target there, right? Because in this population, they are a little bit heavier and with more fat to lose, but eventually you still need to see the weight loss, and then how this body composition, the lean versus the fat loss, kind of play into the place, make your overall weight loss even more impressive if number-wise it is lower than the incretin.
Yeah. I think this is the evolution of weight loss versus body composition improvement, and what does that look like in a vis-a-vis scale weight. Nonetheless, we will talk about what people really refer to oftentimes on weight loss is trying to think about regulatory thresholds. So, what needs to be achieved to various thresholds? I think stepping back to this point, because there is a lot to digest in the question and kind of how to think about it in various segments. I think a lot of this is about what I call the first segment.
This is the kind of, it is oftentimes referred to as kind of the monotherapy, and I think if we are thinking about it differently, because I could argue maintenance is also monotherapy, there is an induction discussion of really what do you need to drive this improvement?
That is the induction component of the drug. There is the combination, and we have a lot of conversations about the idea of what happens when these mechanisms are combined and the ability of what does that mean long term to actually reducing and kind of down-titrating doses of incretins. Some strategics will often refer to this as their definition of maintenance, which is maintaining people on GLP-1s, potentially at a lower dose, alongside INHBE to improve body composition.
The third is this maintenance concept of how do you sustain people on this drug? If we kind of start with the first one, which is where a lot of that question sits, which is, what does that induction component look like on a driver of body composition? I think the regulatory threshold for an approval is still 5% change in total body weight.
I think what we want to see, if we kind of go back to the early data, and what I can say is stepping back across all the cohorts in the study, what we do see is there is a high correlation between baseline adiposity and therapeutic effect. That is important because that is consistent with everything we have seen, both pre-clinically and if we think about the human genetics. If we think about pre-clinically and we share these data at our most recent R&D Day, and I am going to flip the order of what people are usually used to, if we take a lean mouse that is fed a lean diet and we give them INHBE, it is not surprising they do not lose weight. They do not have fat to lose.
If we take a DIO mouse model, which is a representation of an obese mouse model fed a high-fat diet, they have the same body weight reduction as GLP-1s, albeit at a slower rate because they are not doing that 30%-40% lean mass loss at the beginning. With an improvement in body composition. In that weight loss model, we see that coming off of visceral fat, subcutaneous fat, lean mass preservation. That is what we saw. If we go back to the most representative population in this study was the 240. That is the group that had the highest baseline adiposity that we could evaluate on BMI. In that group, we saw a 15% reduction in visceral fat, 5.3% reduction in total body fat, 3.3% decrease in waist circumference.
If we think about INHBE data in general that is out there, it is the most comprehensive data set on the target in that it was visceral fat, it was total fat, it was waist circumference. The constituency of things you need to see, all with preservation of lean mass. That is important as we think about this mechanism is one that drives fat reduction. For those unfamiliar with INHBE, human genetic target, 50% loss of function yields, and these kind of manage this as the human maintenance study. If you are born that way, you do not accumulate abdominal visceral fat or body habitus, increased subcu fats. These are patients who are generally lean in body habitus.
They have low lipid profiles, so a beneficial lipid profile, and they have, in the outcome studies, because in the UK Biobank, they followed these patients out, they have cardiovascular outcome benefits and Type 2 Diabetes outcome benefits. We imagine that human experience, we could recapitulate that on fat reduction and lean body mass preservation. That is in the monotherapy. We could also show in combo, when you add it, you see that reduction additive to the GLP-1. You double the weight loss. The mechanism is all fat. You do not see further loss of lean mass in combination. You just see further fat reduction, which drives body weight reduction.
But probably when, and you will hear me say this again, I think the most interesting data set that was emerging, which is consistent with the human genetics, is the maintenance data we ran, where we did the induction. We had these mice at a steady state of weight loss on semaglutide. We dosed with INHBE and withdrew the sema arm, and there is a placebo and INHBE. Both mice, importantly, so this gets back to the mechanism, went back to hedonic eating. So the caloric consumption went up in both animal groups.
The treated group stayed flat. They did not re-accumulate fat, with the exception of a small bump in body weight, which actually now we know, is just an increase in the lean muscle mass that they kind of get to restore. We know that stabilizes, but do not regain fat.
And if we think about what happens to patients, and this coming out of ObesityWeek, is the most dangerous thing for patients in obesity is weight cycling. Meaning, you go on these therapies, these patients go through a high degree of loss. When they regain their weight back, everybody goes, "Oh, they regain their weight back to starting or a little bit higher than baseline." Exactly what happened in these mice. But what is interesting is, when that weight comes back, it comes back as fat, not as muscle.
So actually, these patients oftentimes have a higher degree of adiposity at the end of the study than when they actually started their therapy to begin with. And that is why when people talk about weight cycling as being potentially dangerous, the goal is that this accumulation of fat continues. The whole mechanism of INHBE is to prevent fat accumulation.
And one of the interesting things to come out of the recent data update we did going into ObesityWeek is, we saw the 240, which is our 12-month follow-up period, that Activin E levels were sustained out at a year. So again, reinforcing our differentiation on siRNA for potential once to twice a year dosing. What we also saw was the body composition of those patients stayed stable. So again, this is a phase I study. We have no diet or exercise requirements, hence why we talked about the beginning. But if we think mechanistically, it is highly encouraging that what was supposed to happen mechanistically if you suppress Activin E is continuing to play out.
I think this idea of where we are going directionally with body composition is important on this induction, but I do think about long term, how are we actually addressing the longitudinal treatment of patients with obesity? The notion of this is maintenance therapy is pretty important.
Yeah. Okay. A couple quick pointed question on the induction monotherapy. How should we think about if you show 5% weight loss, but most of them are, if not all of them, are coming from fat? Would that be exciting and then for you to move forward as a monotherapy? Or on the other side is you can combine these combination and then, I think we saw other INHBE, double whatever other incretin can achieve. That would be more important to move forward.
Yeah. I think, coming out of a number of meetings, just to hear, I think 5% is kind of where that is a regulatory bar for obesity. I think it is less about, is it 5%, is it 6%, is it- The absolute scale weight %, it is what is the quality of that weight loss? And I think what is exciting about what 5% means is it is not 5% on a scale where people go, "Well, I am looking at incretins, and is 5% really meaningful?" If we look at the BELIEVE data set, at the first time point when they cut it, like 30%-40% of that body weight reduction is all lean skeletal muscle. That is lean mass loss coupled with fat.
If what we are seeing over time is a substantial change in body weight, take 5%, but all of that weight, and if we think about the differential between how much a pound you lose in fat versus what a pound you need to lose in terms of muscle, they are very different in what that change is for individuals. So 5% body weight reduction that is all coming off of fat, subcutaneous fat, visceral fat, is a substantial shift for these patients.
That is why, frankly, the agency uses that as the cutoff, because it is in their belief, that that was an evaluation that that would be clinically meaningful reduction in total body weight. What is also important, if we go back to the FDA guidance of the 5%, is the FDA doubling down on quality of the weight loss that is delivering that.
I think it is really to address this notion that what is damaging to individuals long-term in health is subcutaneous fat and visceral fat. A substantial reduction would absolutely be clinically meaningful to these individuals if they could take a dose, where we are looking again about a medicine that you get once or twice a year, that could cause a substantial shift in outcomes, benefits, which would come from that % body weight reduction.
How should we think about the kinetics? The trial is going to run longer term, but when you are going to update the street, I think you said you are going to decide if you will release the three months data. We know three months probably is a body composition more likely. What is going to trigger you to release data early, and then how should we think about the six months and nine months without getting towards the 5%, make this more achievable at the 12 months?
Yeah, I think it is a great question because it was what we wanted to answer sooner rather than later. On Friday, when we provided the update going into ObesityWeek, we were clear in that announcement that we would look at the six-month data. One, we wanted to take out any doubt that we are looking at data and making that decision, so it is a blinded study, we are not.
Two, exactly to your point, I think we can all reflect on past data release so that we know that this has a body composition improvement. We know, to your point, on what are people looking for beyond just body composition. They are looking for shifts that kind of project towards what could be a regulatory achievable outcome. To that end, three months is a very clear body composition time point.
We see that in every study that we have run on this, at that early time point, lean muscle mass goes up. That is awesome. You want that to happen. That means these patients are actually getting muscle mass restoration, and they are losing fat. That is also important. But it is a mathematical equation that if you gain muscle and you lose fat, that that gain in muscle offsets that change. By six months, and if I reflect on this conference kind of sitting last year, where there was a lot of enthusiasm at body composition shifts, and we saw the lean mass go up, and we saw fat come down, I think there was a lot of enthusiasm. We reminded people, like, the biggest concern at that conference discussion was, is lean mass going to keep going up?
Is it going to become harder and harder to see the algebra work out to how are you going to see % body weight reduction? We were very clear at that point in time that every study we've run, that we've seen in other medicines that have mechanisms that are similar in terms of lean mass preservation, that by three months, you see a plateauing of lean muscle mass. That's exactly what we saw. We had the data release in March. Lean mass has plateaued, so it didn't continue to get higher, and body fat reduced. That concept of if we look out and why the six-month data becomes important is, that's where the card gets turned over.
Then to your point, it's six months, nine months, 12 months, that drives an equation where lean mass stays the same, fat should continue so long as Activin E is suppressed, like we've seen before. So long as the baseline adiposity is there, you should continue to see that. Hopefully, it was helpful to us, we shared this at earnings recently, that we did do, because the question in the minds that are all, what's the baseline characteristics looking like going into this study? We believe that it would be pretty clear that when you run an obesity phase II/III study, patients have very similar characteristics going there. If you picture that slide where there's a box at the top, there's a clustering of not just BMI increases, but importantly, that translating to increases in adiposity, visceral fat, and subcutaneous fat.
We did provide the update that not only is the BMI consistent in this enrollment, as we're saying, so these patients have high BMIs, as would be expected in this study. So that's important. Because we have baseline MRI, we also did the QC on baseline adiposity. What we could say is, that is correlating that these patients do have higher baseline adiposity in addition to high BMI. As we kind of set a study up for a medicine whose whole purpose is to reduce fat off of that higher adiposity, which is what we saw in the phase I think it's encouraging that the study's set up to deliver the patient population that we need to study in with the mechanism that we have.
Based on the baseline characteristics and then your previous phase I data in a relatively healthy patient, and then your PK/PD modeling, do you expect this six months will getting closer to 5%, or is it a high linearity after six months to 12 months? Because the ultimate goal is 12 months, 5%. Just be clear, right? That's the goal.
We're not changing that goal.
Yeah. Then in the six months, it will be more linear with your halfway, or is it kind of a plateau from six to 12 months? I don't know if we have the answer for the kinetics.
Yeah, I'm always careful of trying to translate mouse kinetics to human kinetics, simply because of metabolic rates. I think what's encouraging, I always look back at the DIO and say, "Look, it translated for incretins." Weight reduction was similar for incretins, so we know that it can get there. Now, what that year translation takes in, we should see that curve shift at six months. I think we relatively believe that by three months you lose fat, and you have still fat to lose at six months, and muscle stabilizing, then body weight gets reduced. Again, I think the simplicity of really thinking about it as a mathematical equation of lean mass increases body weight and fat reduction decreases it. So long as that proportion stays, we should see that curve translate at the six-month time point.
Then it becomes easier to project, to your point on, where do we think it'll need to be on a timeline? But step one is right patient population. We now have conviction that we're there. Now it's about following it, and I think six months, as we said, is the right time to do that first look and see where we'll be on that trajectory.
Got it. Your maintenance, which we agree, this is a very important setting to address. For the, what is the incretin level at the end of enrolling into the maintenance? The top dose and at the maximum weight loss, and then the goal is to maintain. How much maintain will be successful, and how likely they can even increase the weight loss?
No, it is a very important question, and the one that the study is set up to answer. The update we provided on Friday, which I think, again, going to ObesityWeek is really important, is I know there was a lot of waiting to see what the maintenance study is going to look like. I give the team an enormous amount of credit for spending time really thinking about efficiency. Given to your point of needing to do run-ins and think about how do you do that, to think about that as an entirely different trial design when we have already initiated combination as part of the study, right? There is combination.
That has tirzepatide. We have a placebo, we have INHBE where we are looking at that monotherapy, right, with just tirzepatide alone with placebo, and we have got INHBE with tirzepatide to look at the additivity. Those patients are all going to reach their nadir, right? That is part of the definition of the combination study is to see the effect size of tirzepatide placebo versus INHBE, so the additivity. The view was, rather than waiting again, we have just invested the patient's time in getting to whatever the treatment goal is going to be. The advantage is, well, that is great. Now all we have to do is rerun the study we ran in our preclinical models of dose the patient, withdraw the tirzepatide, and then we will look at the recovery rate.
One of the interesting things that the experience has taught us, given that a number of these studies have been run across incretins, is the rate of return of body weight post-cessation is pretty fast.
The ability to see signals very early on as to blunting that curve is something we will be able to capture in that study. To that point, that is the advantage then of following those patients out. That study has a follow-up period of, we can actually follow them up to a year if we want to look at the cessation piece and what maintenance starts to look like. Efficiently within one trial design where those patients are already captured, already being studied, already well part of a clinical trial to look at the efficacy, we are going to be able to look at that recovery rate on maintenance. We are excited to do that because the data is very strong for maintenance.
If we think about that area, it is an open space where people are trying to figure out what is the best way to do that, and the best that people really have come up with is various dosing regimens of medicines that patients do not want to stay on. From a tolerability and other standpoint, the ability to kind of think orthogonally and say, "Get patients on a once to twice a year medicine so that they can then move forward," I think maintenance is a very promising application for this medicine.
I should say, as part of this holistic study, and really to build on the label, INHBE has a whole bunch of other features that are associated with the genetics beyond just fat reduction. These patients have improvements in hemoglobin A1c, they have reduced risks of liver disease and liver fat and inflammation.
Part of this study will enable us to actually build on the label for not just a body composition improvement, weight reduction, but actually all of the other orthogonal features that we ascribe to GLP-1s in terms of outcome benefits. We will be able to look at Type 2 Diabetes in this study by looking at hemoglobin A1c levels.
We will be able to look at MASH as a potential indication because we have MRI-PDFF, and we will be looking at liver fat accumulation. We will be able to look at other lipid levels as well as we think about cardiometabolic profile. I think in totality as we come out of this, we were very disciplined that the most important thing to do is make sure if we are going to run this study, that we run it where data becomes definitive and usable, as opposed to exploratory.
This study is well-powered for each one of these endpoints to be able to give us a signal, assess that signal, and really come out of this trial with a very clearly defined path forward for where INHBE is going to fit as a therapeutic profile.
Excellent. All right. We don't have too much time to talk about the other pipeline, but you got alignment for the AATD, which is, I think the study design is pretty novel, and then compared to other modalities. My question actually is, how likely other AATD program will get a similar treatment as you got, like the same trial supporting accelerated approval and the full approval? I know you don't want to disclose too much because there's a competitive edge, for sure. But just in terms of this is-
Yeah.
More unique to Wave or more unique to RNA editing or something unique about it?
Well, the nice thing is I don't think this is unique to Wave.
Okay.
I think what was unique is the approach the team took to it. I think too often, and I know I only have like 20 seconds, but I think it's important. Too often we've seen in rare disease, the challenge is everybody runs very quickly to the accelerated approval endpoint. Small number of patients, get there very quickly, and what I call drop the drawbridge, and then what do we see? I mean, DMD is another great example of this. You lower it, multiple companies go in to pursue it because the perception is, okay, the bar is set for everyone now because that's setting a regulatory paradigm and threshold, and everybody runs in. And then everybody's got to run their confirmatory studies and then continue to often times we see this delay and this lag to getting there.
What I think was highly efficient about this design was, one, truncate the time to getting to a full approval, opening up U.S. and Europe. As it's at least consistently being seen, MFN in the rare disease place is not playing as big a role, so you really can think about potential for two markets in that opportunity set. By doing that, you've already now enrolled essentially your confirmatory study, so you've got a path forward where you're not trying to find these patients compete.
When you deliver that study, you're now lifting up the drawbridge and you're saying, "Actually, anybody else who's come through actually has to run a superiority study to the approved program, which we've done in a very short period of time." What, and again, credit and kudos, and I'm looking at Chris and Kyle, to the team is, we haven't forgone in that conversation what everybody's still looking for, which is an interim analysis for potential accelerated approval that you can use on all of that same pathway. So you've been able to kind of feed two birds with one hand, which is the expediency that we often ascribe to accelerated approvals and the efficiency of getting to patients very quickly.
To the end, realizing that in a competitive arena, how quickly can you change the chessboard of what that's going to look like, do that with a well-described study. I think the challenge for why different companies have an approach is, we're not afraid to say, "You know what? It's a big enough population, we can run a placebo-controlled study for a full approval with endpoints that we like and do that." What we're seeing, particularly amongst the DNA editing group, is a reluctance to say, "We need to run these smaller studies with fewer patients." Probably has a lot to do with the cost of the therapies, that we can do this with smaller studies potentially without the placebo.
I think it's really a view of, we took that we could do this highly efficiently, highly effectively, in a cost-effective manner too, to deliver that endpoint and deliver the potential for a registrational accelerated approvals position as well. Again, I think that's the advantage. I do think for anybody who wants to do that, I don't think that there's a uniqueness from the agency of saying, "That's special." You have to have the desire to do both and the plan to do both, and if you can execute that, I think that's going to be best for patients. I think long-term, accelerating this medicine. I think it's great for the program.
Excellent. All right.